5 Crucial Insights into Low VWF QL: Uncovering a Distinct Cause of Bleeding
Blood Journals Portfolio, an official portfolio of ASH journals, shared a new sudy on X:
”Mild isolated functional VWF defects in the 30 to 50 IU/dL range are common and are associated with significant bleeding in some patients.”
Read the full article here.
The recently published article ‘Clinical phenotype and pathophysiological mechanisms underlying qualitative low VWF‘ by Ferdows Atiq et al. in Blood, sheds light on the significant complication risk for people with mild isolated VWF defects.
Emerging data from these combined cohorts in Ireland and Erasmus MC reveal that qualitative low von Willebrand factor (low VWF QL)—characterized by isolated reductions in VWF activity (30–50 IU/dL) despite normal antigen levels—accounts for approximately 50% of patients with low VWF.
Unlike type 2 von Willebrand disease (VWD), low VWF QL represents a distinct clinicopathological entity marked by significant bleeding phenotypes in many affected individuals.
Importantly, these functional defects are primarily driven by impaired VWF biosynthesis in endothelial cells, independent of known genetic variants.
These findings underscore the need for refined diagnostic approaches and tailored management for patients with mild functional VWF defects.

All the latest scientific advancements in the field of bleeding disorders featured in Hemostasis Today.
-
Jun 7, 2026, 12:28Thrombosis in Cancer Patients: Why It Happens and How We Treat It Today
-
Jun 7, 2026, 12:01Addressing Real-World Challenges in Thrombosis Care Through Case-Based Learning – Thrombosis Canada
-
Jun 7, 2026, 11:46Zehraan Ibni Akbar: Transforming Laboratory Data into Clinical Decisions Through Platelet Disorder Recognition
-
Jun 7, 2026, 11:31Alice Zerbinati: Y-90 Radioembolization Expands Curative Options for Advanced Hepatocellular Carcinoma
-
Jun 7, 2026, 09:26Filimon Dagnew Bezabih: SNMMI Honors 18F-GP1 PET Imaging for Innovation in Thrombosis Detection
-
Jun 7, 2026, 06:57Chandran Nadarajan: Targeted Endovascular Thrombolysis Offers Organ-Saving Benefits in Vascular Occlusions
-
Jun 7, 2026, 05:50Sayan Koley: Lupus Anticoagulant – A Key Marker in Thrombosis Risk Assessment
-
Jun 7, 2026, 05:45Nicolas Hubacz: Watching a Heart Build Its Network
-
Jun 7, 2026, 05:40New Evidence Highlights the Urgent Need for Gender-Inclusive Bleeding Disorders Research – EHC